News headlines about Bristol-Myers Squibb (NYSE:BMY) have trended positive recently, Accern Sentiment Analysis reports. The research group identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Bristol-Myers Squibb earned a media sentiment score of 0.33 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 45.9934904672886 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the media headlines that may have effected Accern’s scoring:
- Bristol-Myers Squibb (BMY) Granted Approval by Japanese Ministry of Health for Opdivo (nivolumab) Based on 3 Study … – StreetInsider.com (streetinsider.com)
- AbbVie (ABBV), Bristol-Myers Squibb (BMY) Announce Pact to Evaluate Therapeutic Regimen in Advanced Solid Tumors – StreetInsider.com (streetinsider.com)
- BRIEF-Bristol-Myers says FDA approves Opdivo(Nivolumab) injection for intravenous use in certain patients (reuters.com)
- Bristol-Myers Squibb’s Opdivo® (nivolumab) Receives FDA Approval for the Treatment of Hepatocellular Carcinoma Patients Previously Treated with Sorafenib (finance.yahoo.com)
- Bristol-Myers Reports Approval Of Opdivo For Recurrent Gastric Cancer In Japan (markets.businessinsider.com)
A number of equities research analysts have recently weighed in on BMY shares. Cowen and Company reissued a “hold” rating and set a $65.00 target price on shares of Bristol-Myers Squibb in a report on Tuesday, September 19th. Jefferies Group LLC lifted their target price on Bristol-Myers Squibb from $66.00 to $72.00 and gave the stock a “buy” rating in a report on Monday, September 11th. Vetr raised Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating and set a $62.23 target price for the company in a report on Wednesday, July 12th. Hilliard Lyons downgraded Bristol-Myers Squibb from a “long-term buy” rating to a “neutral” rating and set a $65.00 target price for the company. in a report on Tuesday, September 12th. Finally, Goldman Sachs Group, Inc. (The) reissued a “buy” rating and set a $63.00 target price on shares of Bristol-Myers Squibb in a report on Wednesday, August 9th. One investment analyst has rated the stock with a sell rating, eleven have issued a hold rating and nine have assigned a buy rating to the stock. Bristol-Myers Squibb presently has a consensus rating of “Hold” and an average target price of $62.20.
Bristol-Myers Squibb (BMY) opened at 63.36 on Friday. Bristol-Myers Squibb has a 52 week low of $46.01 and a 52 week high of $63.55. The firm’s 50-day moving average price is $58.94 and its 200 day moving average price is $56.02. The firm has a market cap of $103.91 billion, a P/E ratio of 23.14 and a beta of 1.18.
Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share for the quarter, beating the consensus estimate of $0.73 by $0.01. Bristol-Myers Squibb had a return on equity of 32.33% and a net margin of 22.66%. The firm had revenue of $5.14 billion for the quarter, compared to analysts’ expectations of $5.09 billion. During the same quarter last year, the firm posted $0.69 EPS. The company’s revenue was up 5.6% compared to the same quarter last year. Equities analysts forecast that Bristol-Myers Squibb will post $2.98 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, November 1st. Shareholders of record on Friday, October 6th will be issued a $0.39 dividend. The ex-dividend date is Thursday, October 5th. This represents a $1.56 annualized dividend and a dividend yield of 2.46%. Bristol-Myers Squibb’s payout ratio is currently 56.73%.
In other Bristol-Myers Squibb news, Director Theodore R. Samuels II purchased 6,000 shares of the stock in a transaction on Wednesday, August 2nd. The shares were purchased at an average price of $55.94 per share, with a total value of $335,640.00. Following the acquisition, the director now directly owns 18,000 shares in the company, valued at approximately $1,006,920. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, SVP Joseph C. Caldarella sold 9,340 shares of the firm’s stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total value of $560,400.00. Following the completion of the sale, the senior vice president now directly owns 46,297 shares in the company, valued at approximately $2,777,820. The disclosure for this sale can be found here. Company insiders own 0.23% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Bristol-Myers Squibb (BMY) Getting Positive Media Coverage, Study Shows” was reported by TrueBlueTribune and is the property of of TrueBlueTribune. If you are viewing this report on another site, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The legal version of this report can be viewed at https://www.truebluetribune.com/2017/09/24/bristol-myers-squibb-bmy-getting-positive-media-coverage-study-shows.html.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.